This study shows that the supramolecular arrangement of proteins in nanoparticle structures
predicts nanoparticle accumulation in neutrophils in acute lung inflammation (ALI). We …

Since the approval of rituximab in 1997, monoclonal antibodies (mAbs) have become an
increasingly important component of therapeutic regimens in oncology. The success of mAbs …

Ex vivo-loaded white blood cells (WBC) can transfer cargo to pathological foci in the central
nervous system (CNS). Here we tested affinity ligand driven in vivo loading of WBC in order …

Drug delivery research pursues many types of carriers including proteins and other
macromolecules, natural and synthetic polymeric structures, nanocarriers of diverse compositions …

Drug targeting to inflammatory brain pathologies such as stroke and traumatic brain injury
remains an elusive goal. Using a mouse model of acute brain inflammation induced by local …

The use of drug delivery systems (DDS) is an attractive approach to facilitate uptake of
therapeutic agents at the desired site of action, particularly when free drug has poor …

Red blood cells (RBC) have great potential as drug delivery systems, capable of producing
unprecedented changes in pharmacokinetics, pharmacodynamics, and immunogenicity. …

Molecular targeting of nanoparticle drug carriers promises maximized therapeutic impact to
sites of disease or injury with minimized systemic effects. Precise targeting demands …

The bloodstream is the main transporting pathway for drug delivery systems (DDS) from the
site of administration to the intended site of action. In many cases, components of the …

Accurate prediction of the clinical pharmacokinetics of new therapeutic entities facilitates
decision making during drug discovery, and increases the probability of success for early …